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Chronic	  lymphocytic	  leukemia	  (CLL)	  is	  the	  most	  common	  adult	  leukemia	  in	  the	  
western	   world.	   Pathogenic	   mechanisms	   involve	   multiple	   external	   events	   (such	   as	  
microenvironmental	  and	  antigenic	  stimuli)	  and	  internal	  events	  (genetic	  and	  epigenetic	  
alterations)	  that	  are	  associated	  with	  the	  transformation,	  progression	  and	  evolution	  of	  
CLL.	   CLL	   is	   characterized	   by	   an	   accumulation	   of	   mature	   B-­‐cells	   in	   peripheral	   blood,	  
bone	  marrow	  and	  lymphoid	  tissues.	  Extracellular	  stimuli	  play	  an	  important	  role	  in	  the	  
development	  and	  maintenance	  of	  neoplastic	  cells.	  B-­‐CLL	  cells	  proliferate	  and	  activate	  
pathogenic	  signaling	  pathways	  in	  anatomical	  structures	  known	  as	  proliferation	  centers,	  
which	  are	  usually	  more	  conspicuous	  in	   involved	  lymph	  nodes	  (1).	   Its	  clinical	  course	  is	  
quite	  heterogeneous,	  whereby	  some	  patients	  progress	  rapidly	  and	  have	  short	  survival,	  
whereas	   others	   have	   a	  more	   stable	   clinical	   course	   that	  may	  not	   need	   treatment	   for	  
years.	  	  
Several	   clinical	   and	  biological	   prognostic	   factors	   for	   CLL	  have	  been	   identified,	  
such	   as	   the	   Rai	   and	   Binet	   clinical	   staging	   systems,	   specific	   cytogenetic	   alterations,	  
mutational	  status	  of	  immunoglobulin	  (IgHv)	  genes,	  TP53	  mutations	  and	  the	  expression	  
levels	  of	  CD38	  and	  ZAP70.	  More	  recently,	  massive	  sequencing	  data	  have	  revealed	  new	  
genetic	  alterations,	  some	  of	  which	  have	  a	  significant	  impact	  on	  the	  clinical	  course.	  Of	  
these,	   mutations	   in	   the	   NOTCH1	   and	   SF3B1	   genes,	   which	   are	   associated	   with	   an	  
adverse	  clinical	  outcome,	  are	  emerging	  as	  the	  most	  frequent	  mutations	  in	  CLL	  (2).	  
The	  NOTCH1	  gene	  codes	  for	  a	  trans-­‐membrane	  receptor	  that	  regulates	  critical	  
cellular	  functions	  such	  as	  proliferation,	  apoptosis	  and	  differentiation,	  and	  is	  associated	  
with	   tumorigenesis.	   NOTCH1	   signaling	   is	   initiated	  when	   a	   ligand	   from	   the	   Jagged	   or	  
Delta	  families	  binds	  the	  receptor	  and	   induces	  a	  cascade	  of	  proteolytic	  processes	  that	  
results	   in	   the	   release	   and	   nuclear	   translocation	   of	   the	   NOTCH1	   intracellular	   domain	  
(NCID).	   This,	   in	   conjunction	   with	   the	   transcription	   factor	   CBF1/RBP-­‐Jk,	   leads	   to	   the	  
activation	  or	  repression	  of	  its	  target	  genes	  (3,	  4).	  	  
Although	  a	  considerable	  number	  of	  studies	  have	  addressed	  the	  consequences	  
of	  NOTCH1	  and	  SF3B1	  mutations	  in	  CLL	  (2),	  few	  have	  so	  far	  analyzed	  the	  frequency	  and	  
biological	  impact	  of	  these	  mutations	  in	  lymph	  nodes	  (LN)	  affected	  by	  CLL	  (lnCLL).	  There	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is	  a	  growing	  interest	  in	  therapeutic	  targeting	  of	  NOTCH1	  activation	  signaling	  in	  tumors	  
with	   agonists	   such	   as	   γ-­‐secretase	   inhibitors	   (5).	   It	   has	   also	   been	   proposed	   that	  
mutation-­‐independent	  NOCH1-­‐activation	  contributes	  to	  tumor	  cell	  growth	  and	  survival	  
(6,	  7).	  	  
Therefore,	  we	  have	   analyzed	   the	   frequency	   of	  NOTCH1	   and	  SF3B1	  mutations	  
and	  the	  functional	  status	  of	  the	  NOTCH1	  pathway	  through	  the	  expression	  analysis	  of	  
NOTCH1-­‐induced	  targets	  in	  a	  series	  of	  samples	  of	  lnCLL.	  
The	   first	   step	   was	   the	   analysis	   of	   NOTCH1	   and	   SF3B1	   mutations	   in	   the	   LN	  
infiltrated	  with	  CLL.	  The	  series	  included	  155	  LN	  samples	  from	  147	  patients,	  who	  were	  
biopsied	  at	  diagnosis	  or	  during	  the	  course	  of	  the	  disease	  (Supplemental	  Materials	  and	  
Methods).	   The	   characteristics	   of	   the	   series	   are	   summarized	   in	  Table	   1.	  NOTCH1	   and	  
SF3B1	   mutations	   were	   successfully	   analyzed	   in	   140	   and	   142	   samples	   by	   qPCR	  
respectively,	   finding	   that	   32/140	   (22.8%)	  were	  positive	   for	   the	  p.P2515fs*4	  NOTCH1	  
mutation	  and	  14/142	  (9.8%)	  for	  the	  p.K700E	  SF3B1	  mutation.	  As	  this	  SF3B1	  mutation	  
constitutes	  only	  around	  50-­‐60%	  of	  all	  SF3B1	  mutations	  identified	  in	  CLL,	  we	  also	  study	  
exons	   14	   and	   16,	   in	   which	   most	   of	   the	   other	   mutations	   reside.	   Although	   capillary	  
sequencing	   is	   a	   less	   sensitive	  method	   than	   qPCR,	  we	  were	   still	   able	   to	   identify	   four	  
additional	  SF3B1	  mutations	  in	  exon	  14	  and	  none	  in	  exon	  16.	  Therefore,	  18/142	  (12.7%)	  
SF3B1	  gene	  mutations	  were	  detected.	  Three	  out	  of	  132	  samples	  showed	  a	  mutation	  in	  
both	  genes	  (Table	  2).	  When	  comparing	  the	  rate	  of	  mutations	  in	  both	  genes	  in	  samples	  
taken	   at	   the	   time	   of	   diagnosis	   or	   progression,	   no	   significant	   differences	  were	   found	  
(Table	   2).	   Samples	   at	   diagnosis	   and	   during	   progression	   were	   available	   for	   eight	  
patients.	  NOTCH1	  status	  did	  not	  change	  in	  any	  of	  the	  patients	  (2	  mutated	  and	  6	  non-­‐
mutated),	  while	  one	  acquired	  an	  SF3B1	  mutation	  during	  progression.	  	  
We	   found	   that	   although	   the	   percentage	   of	   cases	  with	  mutated	   SF3B1	   at	   the	  
time	   of	   diagnosis	   (11.7%)	   was	   similar	   to	   that	   of	   other	   series	   analyzed	   in	   peripheral	  
blood	   (PB)	   lymphocytes	   (2),	   the	  NOTCH1	  mutation	   rate	  we	   found	   in	   lnCLL	   (24.5%	  at	  
diagnosis)	  seems	  to	  be	  higher	  than	  in	  other	  studies	  performed	  in	  PB	  samples,	  in	  which	  
the	  percentages	  of	  mutations	  range	  from	  8%	  to	  31%	  (8,	  9)	  depending	  on	  the	  series	  and	  
its	  characteristics.	  The	  lowest	  values	  (less	  than	  15%)	  were	  obtained	  from	  the	  analysis	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of	  samples	  taken	  at	  diagnosis	  and	  the	  highest	  were	  found	  in	  patients	  transformed	  to	  
Richter	  syndrome	  (8)	  or	  who	  showed	  refractoriness	  to	  treatment	  (10).	  It	  is	  also	  higher	  
than	  the	  frequency	  found	  in	  a	  different	  series	  of	  CLL	  PB	  taken	  at	  the	  time	  of	  diagnosis	  
analyzed	   in	   our	   laboratory	   using	   the	   same	  method	   in	  which	  we	   found	   12%	  of	   cases	  
with	  p.P2515fs*4	  NOTCH1	  mutation	  (data	  not	  shown).	  	  
We	  only	  analyzed	  the	  p.P2515fs*4	  mutation,	  which	  accounts	  for	  around	  80%	  of	  
all	  NOTCH1	  mutations	  reported	  in	  CLL	  (from	  66%	  to	  98%	  (11))	  and	  therefore	  the	  real	  
percentage	  of	  mutated	  cases	  in	  our	  lnCLL	  might	  be	  even	  higher.	  This	  could	  be	  due	  to	  
the	   greater	   aggressiveness	   of	   lnCLL	   and/or	   to	   the	   high	   sensitivity	   of	   the	   qPCR	  
technique	  used	  for	  mutation	  detection.	  
We	  next	  analyzed	  the	  association	  of	  NOTCH1	  and	  SF3B1	  mutations	  in	  samples	  
taken	  at	  diagnosis	  with	  patient,	  clinical,	  biological	  and	  cytogenetic	  characteristics.	  We	  
found	   no	   significant	   associations	   between	   the	   presence	   of	   NOTCH1	   or	   SF3B1	  
mutations	   and	   any	   biological	   and	   clinical	   characteristics,	   or	  with	   overall	   survival	   and	  
time	  to	  treatment	  (Table	  S1	  in	  the	  Supplementary	  Information).	  
The	   expression	   of	   NOTCH1	   itself	   together	   with	   NOTCH1	   targets,	   including	  
NFATc1,	  p52,	  p50,	  C-­‐MYC,	  MUM1,	  XBP1s,	  LEF	  and	  HES1	  (3,	  4,	  12-­‐14),	  and	  Ki67,	  were	  
analyzed	  by	  immunohistochemistry	  in	  the	  155	  CLL	  paraffin	  samples	  and	  in	  six	  samples	  
of	   reactive	   lymphoid	   tissue	   included	   in	   the	  Tissue	  Micro	  Arrays	   (TMA)	   (Supplemental	  
Materials	  and	  Methods).	  	  
Lymphocytes	   in	   reactive	   LN	   exhibited	   mainly	   cytoplasmic	   expression	   of	  
NOTCH1,	   NFAT,	   p52	   and	   p50.	  MUM1	   expression	   was	   restricted	   to	   plasma	   cells	   and	  
scattered	  cells	  within	   the	  germinal	   centers,	  XBP1	  only	   recognized	  plasma	  cells,	  while	  
MYC,	  LEF1	  and	  HES1	  expression	  were	  negative	  in	  normal	  B-­‐cells.	  
NOTCH1	  nuclear	  accumulation	  was	  analyzed	  with	  a	  rabbit-­‐mAb	  recognizing	  the	  
NICD1	  epitope	  (15),	  a	  surrogate	  of	  NOTCH1	  activation,	  and	  was	  detected	  in	  both	  23/29	  
(79.3%)	  of	  NOTCH1-­‐mutated	  case	  sand	  in	  82/91	  (90%)	  of	  NOTCH1-­‐wild-­‐type	  cases.	  This	  
means	   that	   in	   a	   large	   proportion	   of	   samples	   (105/120,	   87.5%),	   NOTCH1	   could	   be	  
detected	  in	  the	  nuclear	  compartment	  of	  the	  tumoral	  B-­‐cells	  (mainly	  in	  the	  proliferation	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centers)	  (Table	  S2),	   indicating	  that	  the	  WNT-­‐NOCTH1	  pathway	  is	  frequently	  activated	  
in	  lnCLL,	  irrespective	  of	  the	  presence	  of	  the	  NOTCH1	  mutation,	  as	  has	  been	  previously	  
reported	  by	  others	  (15).	  	  
The	  NOTCH1	  mutation	  was	   associated	  with	   nuclear	   expression	   of	   NFAT	   (χ2	   =	  
8.081,	  p	  =	  0.005),	  NF-­‐kB	  p52	  subunit	  (χ2	  =	  5.841,	  p	  =	  0.016)	  and	  CMYC	  (χ2	  =	  4.077,	  p	  =	  
0.043),	   which	  was	   selectively	   expressed	   in	   the	   proliferation	   center	   B-­‐cells	   (Table	   S2	  
and	  Figure	  1).	  The	  intensity	  and	  selectiveness	  of	  the	  expression	  of	  CMYC	  by	  neoplastic	  
B-­‐cells	  within	  proliferation	   centers	  were	  unexpected,	  being	   similar	   to	   those	   found	   in	  
tumoral	   cells	   in	   Burkitt	   lymphoma	   samples,	   although	   they	   were	   restricted	   to	   the	  
proliferation	  centers	  in	  our	  study	  (Figure	  1).	  Other	  NOTCH1	  downstream	  targets	  (such	  
as	  HES1,	  LEF1	  and	  XBP1)	  were	  also	  diffusely	  expressed	  by	  neoplastic	  B-­‐cells,	  and	  were	  
detected	  in	  mutated	  and	  non-­‐mutated	  samples,	  further	  supporting	  the	  hypothesis	  that	  
the	   WNT-­‐NOCTH1	   pathway	   is	   frequently	   activated	   in	   lnCLL,	   irrespective	   of	   the	  
presence	  of	  the	  NOTCH1	  mutation.	  
However,	  NOTCH1	  nuclear	  expression	  was	  not	  significantly	  associated	  with	  the	  
detection	  of	  any	  of	   the	  markers	  analyzed	   (Table	  S3),	   their	  expression	  being	   found	   in	  
samples	  with	  or	  without	  nuclear	  NOTCH1	  expression.	  	  
The	   NOTCH1	   pathway	   is	   activated	  when	   ligands	   of	   the	   JAG	   or	   Delta	   families	  
bind	   to	   their	   receptors,	   leading	   to	   the	   release	  and	  nuclear	   translocation	  of	  NOTCH1.	  
These	  ligands	  are	  known	  to	  be	  constitutively	  expressed	  in	  B-­‐CLL	  cells	  (7).	  Therefore,	  we	  
decided	   to	   analyze	   JAG1	   expression	   in	   these	   samples.	  We	   found	   that	   31/94	   (31.9%)	  
expressed	   the	   protein	   and	   that	   its	   detection	   was	   associated	   with	   the	   expression	   of	  
some	  NOTCH1	  targets	  such	  as	  LEF1	  (χ2	  =	  7.095,	  p	  =	  0.008),	  MYC	  (χ2	  =	  5.158,	  p	  =	  0.023)	  
and	  MUM1	  (χ2	  =	  5.369,	  p	  =	  0.021),	  although	  not	  with	  NOTCH1	  expression	  itself	  (Table	  
S4)	  as	  NOTCH1	  could	  be	  activated	  by	  mutation	  independently	  of	  JAG1	  presence.	  JAG1	  
was	  expressed	  in	  the	  B-­‐CLL	  cells	  in	  the	  proliferative	  centers	  of	  wild-­‐type	  and	  mutated	  
cases	  in	  dots	  in	  the	  Golgi	  apparatus.	  	  
These	  results	  reflect	  the	  complexity	  of	  the	  NOTCH1	  pathway	  in	  CLL	  as	  it	  could	  
be	   constitutively	   activated	   by	   different	  mechanisms	   including	   gene	  mutation,	   ligand	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activation	   or,	   even,	   by	   the	   participation	   of	   other	  members	   such	   as	   NOTCH2;	   as	   has	  
been	  also	  previously	  reported	  (7).	  	  
In	   conclusion,	  we	   have	   found	   that	   the	  mutational	   frequency	   of	  NOTCH1,	   but	  
not	  of	  SF3B1,	   is	  higher	   in	  LN	  with	  CLL	  cell	   involvement	  than	   in	  other	  series	  analyzing	  
CLL	  PB	  samples.	  
Another	   major	   finding	   of	   this	   study	   is	   that	   NOTCH1	   pathway	   is	   frequently	  
activated	  in	   lnCLL,	   independently	  of	  NOTCH1	  gene	  mutational	  status,	  thus	  suggesting	  
the	   relevance	   of	   NOTCH1	   pathway	   in	   the	   survival	   of	   CLL	   cells,	   and	   the	   existence	   of	  
previously	   reported	   additional	  mechanisms	   of	   NOTCH1	   activation	   (7).	   These	   include	  
the	   stronger	   expression	   of	   NOTCH1	   ligands,	   which	   suggests	   the	   existence	   of	  
autocrine/paracrine	   mechanisms	   that	   could	   lead	   to	   NOTCH1	   signaling	   activation	   in	  
addition	  to	  NOTCH1	  gene	  mutation.	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Table	  1.-­‐	  Summary	  of	  the	  main	  clinical	  and	  biological	  characteristics	  of	  patients	  with	  samples	  
at	  diagnosis.	  
	  
Lymph	  node	  samples	  obtained	  at	  diagnosis	  
Summary	  of	  clinical	  and	  biological	  characteristics	  
Median	  age	  at	  diagnosis,	  years	  (range)	  	   69.8	  (39-­‐89)	  
Male,	  n	  (%)	   65/100	  (65.0%)	  
Binet	  B-­‐C,	  n	  (%)	   36/72	  (82.0%)	  
Unmutated	  IgH,	  n	  (%)	   40/65	  (61.5%)	  
13q	  del,	  n	  (%)	   6/38	  (15.8%)	  
Trisomy	  12,	  n	  (%)	   9/39	  (23.1%)	  
11q	  del,	  n	  (%)	   6/60	  (10.0%)	  
17p	  del,	  n	  (%)	   4/63	  (6.3%)	  
Lymphocytes	  x109/L,	  median	  (range)	   7	  (1-­‐130)	  
CD38-­‐positive,	  n	  (%)	   43/65	  (66.2%)	  
ZAP70-­‐positive,	  n	  (%)	   22/45	  (49.0%)	  
Treatment,	  n	  (%)	   67/134	  (50.0%)	  
Median	  follow-­‐up,	  mo	  (range)	   28	  (0-­‐152)	  
Death	  by	  CLL	   47/100	  (47.0%)	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Table	  2.-­‐	  Summary	  of	  samples	  with	  mutations	  in	  NOTCH1	  and/or	  SF3B1.	  
	  
	   DX	  (%)	   PR	  (%)	   TOTAL	  (%)	  
NOTCH1	  mut	   28/114	  (24.5)	   4/22	  (18.2)	   32/140	  (22.8)	  
SF3B1	  mut	   14/119	  (11.7)	   3/19	  (15.8)	   18/142	  (12.7)	  
Any	  mutation	   39/112	  (34.8)	   8/19	  (42.1)	   44/133	  (33.1)	  
	  	  
Mut:	  mutated;	  DX:	  diagnostic;	  PR:	  progression.	  




Figure	  1.	  (A)	  Negative	  NOTCH1	  expression	  in	  a	  wild-­‐type	  case.	  (B)	  Mild	  NOTCH1	  expression	  in	  a	  
mutated	   case.	   (C)	   Intense	   NOTCH1	   expression	   in	   a	   wild-­‐type	   case.	   (D)	   NFAT	   cytoplasmic	  
expression	   in	  a	  negative	  case.	   (E)	  NFAT	  nuclear	  expression	   in	  a	  positive	  case.	   (F)	  p50	  nuclear	  
expression	   in	   a	   negative	   case.	   (G)	   p50	   nuclear	   expression	   in	   a	   positive	   case.	   (H)	   p52	  
cytoplasmic	  expression	  in	  a	  negative	  case.	  (I)	  p52	  nuclear	  expression	  in	  a	  positive	  case.	  (J)	  myc	  
expression	  in	  the	  proliferation	  center	  of	  a	  wild-­‐type	  case.	  (K)	  JAG-­‐negative	  stain	  in	  a	  mutated	  
case	  (L).	  JAG	  expression	  in	  dots	  in	  the	  Golgi	  apparatus	  of	  a	  wild-­‐type	  case.	  
	  

